Safety of rasagiline for the treatment of Parkinson's disease.
Identifieur interne : 000C97 ( Ncbi/Merge ); précédent : 000C96; suivant : 000C98Safety of rasagiline for the treatment of Parkinson's disease.
Auteurs : Santiago Perez-Lloret [France] ; Olivier RascolSource :
- Expert opinion on drug safety [ 1744-764X ] ; 2011.
English descriptors
- KwdEn :
- Animals, Clinical Trials as Topic (methods), Drug Interactions (physiology), Drug-Related Side Effects and Adverse Reactions (chemically induced), Drug-Related Side Effects and Adverse Reactions (metabolism), Drug-Related Side Effects and Adverse Reactions (prevention & control), Food-Drug Interactions (physiology), Humans, Indans (adverse effects), Indans (pharmacokinetics), Indans (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Serotonin Agents (adverse effects), Serotonin Agents (pharmacokinetics), Serotonin Agents (therapeutic use), Treatment Outcome.
- MESH :
- chemical , adverse effects : Indans, Serotonin Agents.
- chemically induced : Drug-Related Side Effects and Adverse Reactions.
- drug therapy : Parkinson Disease.
- metabolism : Drug-Related Side Effects and Adverse Reactions, Parkinson Disease.
- methods : Clinical Trials as Topic.
- chemical , pharmacokinetics : Indans, Serotonin Agents.
- physiology : Drug Interactions, Food-Drug Interactions.
- prevention & control : Drug-Related Side Effects and Adverse Reactions.
- chemical , therapeutic use : Indans, Serotonin Agents.
- Animals, Humans, Treatment Outcome.
Abstract
Levodopa remains the gold standard treatment for Parkinson's disease (PD), but chronic treatment induces motor fluctuations and dyskinesias. Other dopaminergic agents, such as dopamine agonists, catechol-O-methyl transferase inhibitors and monoamine oxidase B enzyme inhibitors (MAO-B I) have also been developed to treat patients with PD. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease-modifying benefits with apparently good tolerability and safety profile in PD patients.
DOI: 10.1517/14740338.2011.573784
PubMed: 21453201
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000960
- to stream PubMed, to step Curation: 000920
- to stream PubMed, to step Checkpoint: 000920
Links to Exploration step
pubmed:21453201Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of rasagiline for the treatment of Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21453201</idno><idno type="pmid">21453201</idno><idno type="doi">10.1517/14740338.2011.573784</idno><idno type="wicri:Area/PubMed/Corpus">000960</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000960</idno><idno type="wicri:Area/PubMed/Curation">000920</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000920</idno><idno type="wicri:Area/PubMed/Checkpoint">000920</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000920</idno><idno type="wicri:Area/Ncbi/Merge">000C97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of rasagiline for the treatment of Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Expert opinion on drug safety</title><idno type="eISSN">1744-764X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic (methods)</term><term>Drug Interactions (physiology)</term><term>Drug-Related Side Effects and Adverse Reactions (chemically induced)</term><term>Drug-Related Side Effects and Adverse Reactions (metabolism)</term><term>Drug-Related Side Effects and Adverse Reactions (prevention & control)</term><term>Food-Drug Interactions (physiology)</term><term>Humans</term><term>Indans (adverse effects)</term><term>Indans (pharmacokinetics)</term><term>Indans (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Serotonin Agents (adverse effects)</term><term>Serotonin Agents (pharmacokinetics)</term><term>Serotonin Agents (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Indans</term><term>Serotonin Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Indans</term><term>Serotonin Agents</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Drug Interactions</term><term>Food-Drug Interactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Indans</term><term>Serotonin Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa remains the gold standard treatment for Parkinson's disease (PD), but chronic treatment induces motor fluctuations and dyskinesias. Other dopaminergic agents, such as dopamine agonists, catechol-O-methyl transferase inhibitors and monoamine oxidase B enzyme inhibitors (MAO-B I) have also been developed to treat patients with PD. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease-modifying benefits with apparently good tolerability and safety profile in PD patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21453201</PMID><DateCreated><Year>2011</Year><Month>06</Month><Day>13</Day></DateCreated><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-764X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Expert opinion on drug safety</Title><ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Safety of rasagiline for the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>633-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14740338.2011.573784</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Levodopa remains the gold standard treatment for Parkinson's disease (PD), but chronic treatment induces motor fluctuations and dyskinesias. Other dopaminergic agents, such as dopamine agonists, catechol-O-methyl transferase inhibitors and monoamine oxidase B enzyme inhibitors (MAO-B I) have also been developed to treat patients with PD. Rasagiline is a second generation MAO-B I inducing moderate symptomatic and possibly disease-modifying benefits with apparently good tolerability and safety profile in PD patients.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">The safety of rasagiline in early or advanced PD is discussed. Details about clinical trial data, post hoc analysis in the elderly or regarding cognitive or behavioral effects, food-drug interactions and effects on levodopa-induced dyskinesias are given.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Rasagiline is effective and well tolerated in PD as monotherapy or in combination with levodopa. There was no evidence of a difference in tolerability between younger or older PD patients included in published trials. Food interactions studies with tyramine did not provide evidence of clinical concerns. Drug interaction should be monitored. The risk of serotonin toxicity with serotoninergic antidepressants remains insufficiently characterized, while current available data in small groups of subjects suggest a low risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-Lloret</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Drug Saf</MedlineTA><NlmUniqueID>101163027</NlmUniqueID><ISSNLinking>1474-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018490">Serotonin Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Expert Opin Drug Saf. 2012 Mar;11(2):355</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="N">Food-Drug Interactions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018490" MajorTopicYN="N">Serotonin Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21453201</ArticleId><ArticleId IdType="doi">10.1517/14740338.2011.573784</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:21453201
|texte= Safety of rasagiline for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:21453201" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |